SMiLE-seq combines antibody arrays, mechanical trapping, and next-generation sequencing readouts to provide a new platform for characterizing DNA-protein interactions.
The funding will support manufacturing of the firm's Idylla PCR-based diagnostics platform and worker training at its Mechelen, Belgium facility.
Frameshift plans to commercialize two applications: one for data quality control and a second for identifying mutations in rare and Mendelian disorders.
Its first client, Haystack Bio, will use Genecloud to analyze and store single-cell genomics data for a proprietary platform it is developing for the immunotherapy market.
The partners have integrated WashU's VarScan with Appistry's GenomePilot, which provides preconfigured workflows for clinical NGS.
DiaGenomi offers a number of tests that combine DNA analysis with information about lifestyle and medical results to provide disease risk assessments.
The company is currently recruiting early adopters to put Mastermind, its proprietary database of curated genomic variants, through its paces prior to full launch next year.
The sensor features a DNA-based steric hindrance method, and can detect the presence of antibodies in whole blood in less than 10 minutes.
The firm plans to launch several products based on its proprietary machine learning method for identifying variants that alter cellular biochemistry and cause disease.
The firm plans to begin offering a cloud-based version of its software as well as a possible appliance by the end of the summer.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.